Bothell, Wash.-based Nastech Pharmaceutical has entered into an agreement with Procter & Gamble Pharmaceuticals (P&G) to manufacture and supply the investigational PTH1-34 nasal spray for the treatment of osteoporosis, the companies have reported.

Under terms of the supply agreement, Nastech will be the exclusive manufacturer of PTH1-34 and will be responsible for the chemistry, manufacturing and controls sections of the upcoming FDA regulatory submission. Specific financial terms of the agreement were not disclosed.

PTH1-34 is a fragment of the naturally occurring human parathyroid hormone that is an important regulator of calcium and phosphorus metabolism. When given by daily injection, PTH1-34 has been shown to increase bone mineral density and significantly reduce both vertebral and non-vertebral fractures in postmenopausal women.